Investment Thesis
Raphael Pharmaceutical is technically insolvent with negative stockholders' equity of -1.4M and zero revenue generation, indicating fundamental operational failure in a pharmaceutical development or commercialization context. The company is experiencing critical liquidity distress with a 0.03x current ratio and negative free cash flow of -211K, leaving approximately one quarter of cash runway at current burn rates, making near-term survival dependent on external capital injection.
Strengths
- Net losses improved 15.8% YoY, indicating cost reduction efforts
- Minimal operating burn rate of 210K suggests operational wind-down or significant restructuring
- Cash position of 45K preserved despite insolvency, indicating some liquidity management
Risks
- Technical insolvency: negative stockholders' equity of -1.4M means liabilities exceed assets
- Zero revenue with negative operating income of -1.2M indicates complete lack of commercial viability
- Critical liquidity crisis: 0.03x current ratio means total liabilities > 1000x current assets
- Negative free cash flow with <1 quarter of cash runway creates existential survival risk
- Company may lack viable business operations or viable product pipeline
- Massive negative ROA of -2413% indicates severe economic value destruction
Key Metrics to Watch
- Revenue generation or any commercial milestone achievement
- Stockholders' equity trend and capital injection announcements
- Operating cash flow trajectory and cash burn rate
- Form 4 insider filings indicating management confidence changes
Financial Metrics
Revenue
N/A
Net Income
-1.3M
EPS (Diluted)
$0.07
Free Cash Flow
-211.0K
Total Assets
53.0K
Cash
45.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-2,413.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.03x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T00:27:22.452607 |
Data as of: 2025-12-31 |
Powered by Claude AI